• Axel Hoos, Bristol-Myers Squibb, Wallingford, CT, USA
• Bart O. Roep, Leiden University Medical Center, Leiden, The Netherlands
• Cedrik M. Britten, Johannes Gutenberg-University, Mainz, Germany
• Christian Ottensmeier, Southampton University Hospitals, UK
• Christoph Huber, Association for Immunotherapy of Cancer (CIMT), Mainz, Germany
• Cornelius J.M. Melief, Leiden University Medical Center, Leiden, The Netherlands
• Holden T. Maecker, Stanford University Medical Center, Stanford, CA, USA
• Hyam I. Levitsky, Johns Hopkins University School of Medicine, Baltimore, MD, USA
• Jill O’Donnell-Tormey, Cancer Research Institute, New York, NY, USA
• Kunle Odunsi, Roswell Park Cancer Center, Buffalo, NY, USA
• Lloyd J. Old, Ludwig Institute for Cancer Research, MSKCC, New York, NY, USA
• Mark M. Davis, HHMI, Stanford University School of Medicine, Stanford, CA, USA
• Michael Kalos, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
• Pedro Romero, Ludwig Institute for Cancer Research, University Hospital (CHUV), Lausanne, Switzerland
• Sjoerd Van Der Burg, Leiden University Medical Center, Leiden, The Netherlands
• Steffen Walter, Immatics, Tübingen, Germany
• Sylvia Janetzki, ZellNet Consulting, Inc., Fort Lee, NJ, USA

MIATA Panelists

• Adrian Bot, KitePharma, Los Angeles, CA, USA
• Anne Plant, National Institute of Standards and Technology, Gaithersburg, MD USA
• Ashley Xia, NIAID, NIH, Bethesda, MD, USA
• Axel Hoos, Bristol-Myers Squibb, Wallingford, CT, USA
• Bart Roep, Leiden University Medical Centre, The Netherlands
• Cecile Gouttefangeas, University of Tübingen, Germany
• Cedrik M. Britten, Johannes Gutenberg-University, Mainz, Germany
• Chris Taylor, The European Bioinformatics Institute, UK
• Christian Ottensmeier, Southampton University Hospitals, UK
• Craig Slingluff, University of Virginia, USA
• Ena Wang, CHI, NIH, Bethesda, MD, USA
• Enrique Rabellino, Beckman Coulter, USA
• Franco Marincola, CHI,NIH, Bethesda, MD, USA
• Graham Pawelec, University of Tübingen, Germany
• Guido Ferrari, Duke University, Durham, NC, USA
• Holden T. Maecker, Stanford University Medical Center, Stanford, CA, USA
• James Allison, MSKCC, New York, NY, USA
• James Gulley, NCI, NIH, Bethesda, MD, USA
• Janet Siebert, Cytoanalytics, USA
• Jedd Wolchok, MSKCC, New York, NY, USA
• Jeffrey Weber, Moffitt Cancer Center, Tampa FL, USA
• Jonathan Braun, UCLA, Los Angeles, CA, USA
• Josephine Cox, IAVI, Rockville, MD, USA
• Kunle Odunsi, Roswell Park, Buffalo, NY, USA
• Lisa Butterfield, University of Pittsburgh Cancer Institute, PA, USA
• Mario Roederer, VRC, NIH, USA
• Mark M. Davis, HHMI, Stanford University School of Medicine, Stanford, CA, USA
• Maurice O’Gorman, The Children’s Memorial Hospital Chicago, IL, USA
• Michael Kalos, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
• Padmanee Sharma, MD Anderson Cancer Center, Houston, TX, USA
• Patricia D’Souza, NIAID, NIH, Bethesda, MD, USA
• Peter Gottlieb, University of Colorado, USA
• Peter T. Lee, Immunity, Cambridge, MA, USA
• Ronald Rooke, Transgene, Illkirch Graffenstaden, France
• Sacha Gnjatic, LICR, MSKCC, New York, NY, USA
• Samir Khleif, NCI, NIH, Bethesda, MD, USA
• Simone Joosten, Leiden University, The Netherlands
• Sjoerd Van Der Burg, Leiden University, The Netherlands
• Steffen Walter, Immatics, Tübingen, Germany
• Sudeepta Aggarwal, Immune Tolerance Network, Bethesda, MD, USA
• Sylvia Janetzki, ZellNet Consulting, Inc., Fort Lee, NJ, USA
• Tom H. M. Ottenhoff, Leiden University Medical Center, The Netherlands

Names of contributors participating in the public consultation phase and their affiliation: